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Summary
Objective: Platelet-rich plasma (PRP) is a fraction of plasma that contains high levels of multiple growth factors. The purpose of this study was
to examine the effects of PRP on cell proliferation and matrix synthesis by porcine chondrocytes cultured in alginate beads, conditions that
promote the retention of the chondrocytic phenotype, in order to determine the plausibility of using this plasma-derived material for engineering
cartilage.
Design: PRP and platelet-poor plasma (PPP) were prepared from adult porcine blood. Adult porcine chondrocytes were cultured in the pres-
ence of 10% PRP, 10% PPP or 10% fetal bovine serum (FBS) for 3 days. Cell proliferation, proteoglycan (PG) and collagen synthesis were
quantiﬁed, and the structure of newly synthesized PG and collagen was characterized.
Results: Treatment with 10% PRP resulted in a small but signiﬁcant increase in DNA content (þ11%, vs FBS; P< 0.01; vs PPP; P< 0.001).
PG and collagen syntheses by the PRP-treated chondrocytes were markedly higher than those by chondrocytes treated by FBS or PPP (PG;
PRP: þ115% vs FBS; þ151% vs PPP, both P< 0.0001, collagen; PRP: þ163% vs FBS; þ163% vs PPP, both P< 0.0001). Biochemical anal-
yses revealed that treatment with PRP growth factors did not markedly affect the types of PGs and collagens produced by porcine chondro-
cytes, suggesting that the cells remained phenotypically stable in the presence of PRP.
Conclusion: PRP isolated from autologous blood may be useful as a source of anabolic growth factors for stimulating chondrocytes to engi-
neer cartilage tissue.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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International
Cartilage
Repair
SocietyIntroduction
Articular cartilage provides a resilient, low friction, wear re-
sistant joint surface. Properties inherent to adult articular
cartilage, such as a lack of vascularity and a limited num-
bers of chondrocytes, restrict the tissue’s intrinsic capacity
for healing after acute damage, especially if an injury
does not penetrate into the subchondral bone1. In addition,
the tissues formed by spontaneous repair are ﬁbrocarti-
laginous2, having an abnormal biochemical composition
and inferior biomechanical function3. The implantation of tis-
sue-engineered cartilage fabricated in vitro shows clinical
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Received 3 February 2006; revision accepted 10 May 2006.12promise as a method for delivering reparative cells and pre-
formed tissue into articular cartilage defects4e7.
Because human chondrocytes have a relatively low basal
propensity for proliferating and producing extracellular ma-
trix, methods to accelerate the formation of cartilaginous tis-
sue during in vitro culture are of practical importance. The
stimulation of cell proliferation and matrix deposition by ex-
ogenous growth factors during culture shortens the culture
duration required for producing cell-laden tissue, and may
also increase the mass of transplantable tissue.
Growth factors, applied singly or in combination with
cells, have been shown to stimulate cell proliferation and
matrix formation of tissue-engineered cartilage (reviewed
by Hunziker4). However, in most of those studies, fetal bo-
vine serum (FBS) has been used in combination with
growth factors to enhance their stimulatory effects. Alterna-
tively, without FBS, a mixture of growth factors, such as
transforming growth factor-b (TGF-b), ﬁbroblast growth fac-
tor-2 and platelet-derived growth factor (PDGF)8, can be
used to stimulate cell proliferation and matrix formation9.72
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tivation of cells in vitro circumvents the possibility of
disease transmission. Platelet-rich plasma (PRP) is a frac-
tion of plasma that can be produced by centrifugal separa-
tion of whole blood. Because PRP contains multiple
growth factors concentrated at high levels10e12, PRP
from patients is used as an autologous source of growth
factors for soft tissue and bone repair in several clinical
settings13e16. PRP contains multiple growth factors, such
as TGF-b17, PDGF8, epidermal growth factor (EGF)18
and insulin-like growth factor-1 (IGF-1), and these growth
factors induce biological changes in cell proliferation
and matrix metabolism of a variety of connective tissu-
es10e12,19. Because most growth factors found in PRP
have been demonstrated to independently enhance the
cell proliferation and/or matrix production of articular chon-
drocytes, we postulate that autologous PRP, a highly con-
centrated natural combination of growth factors, has the
potential to stimulate cell proliferation and extracellular
matrix metabolism by articular chondrocytes.
The purpose of this study was to examine the effects of
PRP on cell proliferation and matrix synthesis by porcine
chondrocytes cultured in alginate beads in order to deter-
mine the plausibility of using this plasma-derived material
for engineering cartilage.
Materials and methods
ANIMALSdBLOOD AND CARTILAGE COLLECTION
Eight adult (1.0e1.5 years old) minipigs (Sinclair Re-
search Center, Inc., Columbia, MO) were used to isolate
PRP, platelet-poor plasma (PPP), and articular cartilage
with the approval of the authors’ institutional Animal Care
and Use Committee. Animals were ﬁrst anesthetized by
subcutaneous injections of Telazol (4.4 mg/kg, Fort Dodge
Animal Health, Fort Dodge, IA) and Xylazine (2.2 mg/kg,
Xyla-Ject, Phoenix Pharmaceuticals, Inc., St. Joseph,
MO). Blood (55 ml) was drawn from the popliteal vein
with a 14G needle into a 60 ml syringe treated with an an-
ticoagulant, citrate dextrose solution (Boehringer Laborato-
ries Inc., Norristown, PA). After collecting peripheral blood,
the animals were sacriﬁced by intravenously injecting su-
persaturated pentobarbital (Euthanasia B solution, Henry
Schein Inc., Washington Port, NY) and the bilateral elbow
joints were dissected en bloc without opening the joint
capsule.
PREPARATION OF PRP AND PPP
PRP and PPP were isolated from fresh porcine blood
(about 55 ml) using the SYMPHONY 2 Platelet Concentra-
tion System (DePuy Spine, Raynham, MA) according to the
manufacturer’s protocol. Brieﬂy, the blood treated with anti-
coagulant was separated into plasma and hemocyte (eryth-
rocyte and leukocyte) fractions, and then the plasma was
separated into PRP (containing a high number of platelets)
and PPP (containing few platelets) by a continuous
two-step sedimentation. PRP and PPP were clotted by add-
ing a 10% thrombin solution (v/v, 1000 U/ml in 100 mM
CaCl2) to yield a ﬁnal thrombin concentration of 100 U/ml.
Soluble PRP and PPP releasates from the clotted prepara-
tions were isolated by centrifugation (1500 g for 5 min) and
cleared by ultraﬁltration (0.22 mm). These ﬁnal soluble re-
leasates preparations of PRP and PPP were frozen at
80(C until used.PLATELET COUNT ANALYSIS AND QUANTIFICATION
OF A GROWTH FACTOR
The number of platelets in miniature swine whole blood
(before centrifugation) and in isolated PPP and PRP frac-
tions was assessed using the Advia 120 Bayer Hematology
Analyzer (Bayer Diagnostics, Tarrytown, NY). As an indica-
tor for the efﬁcacy of the concentration of growth factors in
PRP, the level of TGF-b in serum made from the whole
blood used to prepare PPP and PRP fractions and in
PPP and PRP releasates was assessed. The PPP and
PRP isolated fractions were clotted with thrombin and
centrifuged to obtain releasates as described above. The
level of TGF-b in serum and in PPP and PRP releasates
was determined using an enzyme-linked immunosorbent
assay method according to the manufacturer’s instructions
(RD Mouse/Rat/Porcine/Canine TGF-beta 1 Quantikine
ELISA Kit, R&D Systems, Inc., Minneapolis, MN).
CHONDROCYTE CULTURE IN ALGINATE BEADS
Following blood collection, articular cartilage was obtained
from the elbow joints and pooled from two or three minipigs
for each cell preparation. Chondrocytes were isolated from
tissues by sequential enzyme digestion with 0.2% pronase
(EMD Bioscience, La Jolla, CA) for 1 h, and 0.025% collage-
nase P (Roche Applied Science, Indianapolis, IN) for 16 h at
37(C, as previously described7. After several washes in Dul-
becco’s modiﬁed Eagle’s medium and Ham’s F-12 medium
(DMEM/F12: Mediatech, Herndon, VA), the cells were resus-
pended in 1.2% low-viscosity sterile pharmaceutical grade
alginate (Keltone LV-(HM), a gift from ISP Alginate Inc.,
San Diego, CA) solution at 4 million cells/ml20. The cultures,
containing nine beads per well in a 24-well plate, were main-
tained in triplicate culture in 0.4 ml of complete medium con-
taining 10% FBS (Hyclone, Logan, UT), 25 mg/ml ascorbic
acid (Sigma-Aldrich, St. Louis, MO), 360 mg/ml L-glutamine
(Mediatech) and 50 mg/ml gentamicin (Invitrogen, Carlsbad,
CA)] in a 5% CO2:95% air incubator at 37(C. The medium in
all cases was changed daily.
CULTURE PROTOCOL FOR THE STUDY OF THE EFFECTS
OF PRP RELEASATE, PPP RELEASATE AND FBS ON CELL
PROLIFERATION AND PROTEOGLYCAN (PG) AND
COLLAGEN SYNTHESIS
After 7 days of culture in complete medium, the cells were
precultured in serum-free medium (SFM), which consisted
of DMEM/F12 with supplements as described above, for
24 h. The cells were then cultured for another 72 h under
three different conditions: FBS (10% FBS in SFM), 10%
PPP (10% PPP releasate in SFM) or PRP (10% PRP relea-
sate in SFM). The cultures were incubated in 0.8 ml of the
respective medium for 72 h without changing the medium
during the treatment period. A preliminary experiment dem-
onstrated that the rate of incorporation of 35S-sulfate into
PGs by cells cultured under these conditions was constant
throughout the 72-h treatment period (data not shown).
MEASUREMENT OF DNA CONTENT
To evaluate cell proliferation during the 72-h treatment
period, the DNA content of alginate beads was determined
using the bisbenzimidazole ﬂuorescent dye (Hoechst
33258: Polysciences, Warrington, PA) method21 with calf
thymus DNA (Sigma-Aldrich) used as a standard. These
DNA values were used to normalize the values obtained
from the following analyses.
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The incorporation of radiolabeled 35S into sulfated PGs
was measured as an indicator of PG synthesis. During
the last 4 h of the 72-h treatment period, the cells were cul-
tured in the presence of 35S-sulfate (ﬁnal concentration:
20 mCi/ml; PerkineElmer Life and Analytical Sciences, Bos-
ton, MA). After the 72-h treatments, the beads and culture
media were collected and the cell-associated and further re-
moved matrix compartments (CM and FRM, respectively)
were separated by dissolving the beads with sodium citrate
followed by mild centrifugation, as previously described20.
The CM fractions were extracted for 48 h at 4(C with 4 M
guanidine-HCl in the presence of proteinase inhibitors20.
The amount of radiolabeled 35S-PGs in the CM and FRM
fractions and in the medium was quantiﬁed by a rapid ﬁltra-
tion assay following precipitation of the glycosaminoglycans
with alcian blue22.
CHARACTERIZATION OF 35S-LABELED PGS
The size of newly synthesized PGs was assessed using
Sepharose CL-2B sieve chromatography under dissociative
conditions, as previously described20. Brieﬂy, CM and FRM
fractions extracted with 4 M guanidine-HCl were chromato-
graphed on a Sepharose CL-2B column. The 35S-PGs in
each fraction were quantiﬁed by liquid scintillation counting.
The void volume (Vo) and total volume (Vt) of the column
were determined using a high-molecular-weight glucose
polymer containing covalently bonded Reactive Blue 2
dye, blue dextran (Sigma-Aldrich), and free 35S-Sulfate, re-
spectively. The partition coefﬁcient (Kd) of PGs in each col-
umn fraction was calculated as follows; (VeVo)/(VtVo)
where Ve represents the elution volume for each column
fraction. Proportions of large and small PGs were calculated
by using a Peak Fit v4.12 software (SeaSolve Software.
Inc., Framingham, MA) that performs nonlinear least
squares curve-ﬁtting using the MarquardteLevenberg algo-
rithm to ﬁnd the minimum value of the sum of the squared
deviations.
MEASUREMENT OF TOTAL PG CONTENT
After dissolving the alginate beads, the matrix compart-
ments (CM and FRM) were separated and digested with pa-
pain (Sigma-Aldrich) at 60(C for 16 h23. The total sulfated
PG content was measured in each compartment using
a modiﬁed dimethylmethylene blue dye-binding method24
in the presence of 0.03% alginate25. The sum of the total
sulfated PG contents of the CM and FRM was used to rep-
resent the total content of PG.
MEASUREMENT OF COLLAGEN SYNTHESIS
The incorporation of radiolabeled proline into pepsin-re-
sistant protein was measured as an indicator of collagen
synthesis. During the last 16 h of the 72-h treatment period,
the cultures were radiolabeled with L-[2,3,4,5-3H]-proline
(ﬁnal concentration: 50 mCi/ml; Amersham Biosciences
Corp., Piscataway, NJ) in the presence of b-aminopropioni-
trile (100 mg/ml, Sigma-Aldrich). After separation of the CM
and FRM, as described above, the CM, FRM and medium
fractions were digested with 0.5 M acetic acid including
pepsin (Sigma-Aldrich; 100 mg/ml) at 4(C for 16 h. An ali-
quot (25 ml) of each sample and 125 ml of 30% trichloroace-
tic acid (TCA; ﬁnal concentration 25%; Sigma-Aldrich) were
pipetted into a well of a 96-well MultiScreen ﬁltration plateassembly with gentle agitation for 1 h at 4(C26. The formed
precipitate, which contained pepsin-resistant 3H-labeled
protein, was collected on the ﬁlter membrane, and unincor-
porated 3H-proline was removed by washing each well
three times with 200 ml of 10% TCA followed by vacuum ﬁl-
tration through the membrane. The membrane in each well
was punched out into a scintillation vial with 500 ml of dis-
solving buffer (2% Sodium Dodecyl Sulfate (SDS) in 0.1 N
NaOH) followed by gentle shaking overnight at 37(C. The
radioactivity of the samples was counted after adding
2.5 ml of Hydroﬂuor scintillation ﬂuid (National Diagnostics,
Atlanta, GA). Although 3H-proline can be incorporated into
other proteins, a major portion of the pepsin-resistant radio-
labeled molecules (greater than 80%) was precipitated
with ammonium sulfate at 30% saturation and identiﬁed
as the a1 chain of collagen molecules when analyzed by
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis
(SDS-PAGE) and ﬂuorography as described below in the
‘‘characterization of 3H-labeled pepsin-resistant proteins.’’
In addition, to assess collagen synthesis more speciﬁcally,
representative samples were analyzed with separation of
3H-hydroxyproline and 3H-proline on reverse-phase high
performance liquid chromatography equipped with an
online radioactivity detector using previously described con-
ditions27. This analysis showed that PRP treatment stimu-
lated formation of 3H-hydroxyproline to an extent similar to
that assessed as 3H-proline-labeled pepsin-resistant pro-
tein (data not shown).
CHARACTERIZATION OF 3H-LABELED
PEPSIN-RESISTANT PROTEINS
The same samples prepared for collagen synthesis were
also used for the analysis of the types of newly synthesized
pepsin-resistant protein. After pepsin digestion, as men-
tioned above, each sample was centrifuged at 12,000 g
for 30 min at 4(C. The supernatants, containing the pep-
sin-resistant collagens, were precipitated by the addition
of ammonium sulfate (176 mg/ml) and incubated overnight
at 4(C. The samples were then centrifuged at 12,000 g
for 30 min at 4(C and the pellet was recovered and resus-
pended in 0.4 M NaCl, 50 mM Tris. The samples were then
dialyzed for 48 h at 4(C against 10 mM Tris containing
CHAPS at 1 mg/ml and protein inhibitors (1 mM N-ethylma-
lemide, 1 mM phenylmethylsulfonyl ﬂuoride, 5 mM EDTA).
The radiolabeled collagens were separated by SDS-
PAGE (Mini-gel, Bio-Rad) in a 7.5% acrylamide gel (reduc-
ing conditions) and detected by ﬂuorography27.
STATISTICAL ANALYSES
All values are reported as the mean standard deviation
of the results of analyses of three separate cultures of nine
beads. Experiments were repeated on at least three sepa-
rate occasions and representative data are presented.
Analysis of variance with Fisher’s Protected Least Signiﬁcant
Difference (PLSD) test as a post hoc test was used to assess
the effect of treatment on DNA content, matrix synthesis
and accumulation.
Results
PLATELET COUNT ANALYSIS OF PRP
Platelet count analysis was performed on whole blood
and PPP and PRP releasates from eight miniature swine.
The concentration of platelets of whole blood (baseline)
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ible with the range of normal values for miniature swine
(217e770 103/ml)28. The platelet concentration system
resulted in a 3.9-fold increase in the platelet count of the
PRP fraction when compared to whole blood (PRP:
1399 174 103/ml, P< 0.0001, vs whole blood; PPP:
157 80 103/ml, P< 0.05, vs whole blood). These data
were compatible with the data obtained from the manufac-
turer for human serum (4.7 fold).
QUANTIFICATION OF GROWTH FACTOR IN PRP
The level of TGF-b in whole blood and in PPP and PRP
releasates was quantiﬁed in eight animals. The level of
TGF-b was signiﬁcantly higher (two fold) in the PRP relea-
sates compared to the serum and/or PPP releasates (se-
rum: 13.8 0.9 ng/ml, PPP: 2.1 0.3 ng/ml, P< 0.001 vs
serum; PRP: 29.1 8.0 ng/ml, P< 0.00-1, vs serum). The
efﬁciency of concentration was lower than that reported in
the human (six fold).
DNA CONTENT
To study the effects of PRP on cell proliferation, the cul-
tures were treated with FBS, PPP or PRP for 72 h and the
DNA content of the alginate beads was measured. Treat-
ment with PRP resulted in a small but signiﬁcant increase
in DNA content when compared to the FBS and PPP
groups (PRP: þ11%, P< 0.01; vs FBS, þ18%, P< 0.001;
vs PPP, Fig. 1).
PG SYNTHESIS
The rate of PG synthesis (per mg DNA) by the PRP-
treated chondrocytes was signiﬁcantly higher than that by
the FBS- or PPP-treated chondrocytes (PRP: þ115% vs
FBS; þ151%, vs PPP; both P< 0.0001, Fig. 2). When the
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Fig. 1. Effect of PRP on cell proliferation of articular chondrocytes
cultured in alginate beads. Isolated chondrocytes encapsulated in
alginate beads were cultured in DMEM/F12 medium containing
10% FBS for 7 days. After serum starvation, the cells were treated
for an additional 72 h with SFM containing 10% FBS, 10% PPP or
10% PRP. The content of DNA was measured using the Hoechst
dye 33258 method as described in the Materials and methods sec-
tion. The increase in DNA content in alginate beads containing
PRP-treated cells was signiﬁcantly higher than in those containing
PPP-treated cells.data were expressed per nine beads, essentially the
same effects were apparent (data not shown). There were
no signiﬁcant differences between PG synthesis by the
FBS- or PPP-treated chondrocytes (PPP vs FBS,
P¼ 0.27). When the distribution of newly synthesized 35S-
PGs between medium and CM was analyzed, no signiﬁcant
treatment-related differences were observed. However,
treatment with PRP signiﬁcantly increased the proportion
(41% vs 30%) of newly synthesized 35S-PGs in the FRM
compared to the treatment with FBS (P< 0.05, Fig. 2).
To assess the phenotypic stability of chondrocytes,
newly synthesized 35S-PGs in the CM and FRM fractions
were puriﬁed and subjected to sieve chromatography on
Sepharose CL-2B under dissociative conditions. 35S-PGs
extracted both from the CM and FRM consisted predomi-
nantly of large molecular weight sulfated PGs (CM, aver-
age Kd¼ 0.27; FRM, average Kd¼ 0.30), which exhibited
a proﬁle similar to that of aggrecan, the major PG synthe-
sized by mature chondrocytes cultured in alginate20. Small
nonaggregating PGs (such as decorin, biglycan etc. [CM;
average Kd¼ 0.65/FRM; average Kd¼ 0.70]) were present
in much smaller amounts (Fig. 3). The size of the large mo-
lecular weight PGs and the proportion of small nonaggre-
gating PGs in the PRP group were similar to those in the
FBS or PPP groups in either the CM or FRM.
PG ACCUMULATION
Chondrocytes cultured in alginate beads for 3 days in the
presence of PRP accumulated signiﬁcantly more sulfated
PGs than chondrocytes in beads cultured in FBS or PPP
(PRP: þ15%, vs FBS, P< 0.001; þ26% vs PPP;
P< 0.0001, Fig. 4). However, when the data were ex-
pressed per mg DNA, there was no signiﬁcant difference
in PG accumulation among the three experimental groups
(data not shown). No signiﬁcant differences in the distribu-
tion of PGs within the CM or FRM were observed (Fig. 4).
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Fig. 2. Effect of PRP treatment on PG synthesis by articular chon-
drocytes cultured in alginate beads. During the last 4 h of the 72-h
treatment period, the cells were radiolabeled with 35S-sulfate
(20 mCi/ml). The amount of radiolabeled 35S-PGs in the CM ex-
tracts, the FRM fractions and the media were quantiﬁed (see the
Materials and Methods section). The rate of PG synthesis by the
PRP-treated chondrocytes was signiﬁcantly faster than that by
the PPP- or FBS-treated cells. The numbers presented in each col-
umn indicate how much PG was present in the CM, FRM and
medium as a percentage of the total 35S-PG in the beads.
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The amount of newly synthesized pepsin-resistant 3H-
protein (per mg DNA), as a measure of collagen synthesis
by PRP-treated cells, was remarkably higher than that by
FBS- or PPP-treated cells (PRP: þ163% vs FBS; þ163%
vs PPP; both P< 0.0001, Fig. 5). Measurement of pepsin-
resistant 3H-protein synthesis per nine beads yielded es-
sentially the same results as the data expressed per mg
DNA (data not shown). There were no signiﬁcant differ-
ences in synthesis between FBS- and PPP-treated cells
(PPP vs FBS; P¼ 0.1). The proportion of newly synthesized
pepsin-resistant 3H-protein within the medium, CM or FRM
did not change as a result of treatment (data not shown).
The proﬁle of newly synthesized pepsin-resistant protein
was evaluated by separation of the 3H-proline-labeled, pep-
sin-resistant proteins incorporated into the CM and FRM
compartments using SDS-PAGE. The results of SDS-
PAGE ﬂuorography revealed that both compartments in
each experimental group contained a similar prominent
band corresponding to the a1 chain of the collagen mole-
cules at 95 kDa (Fig. 6). An a2 chain, that would have
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Fig. 3. Characterization of newly synthesizedPGs in theCMandFRM
fractions. Sepharose CL-2B molecular sieve chromatography of 35S-
PGs isolated from beads cultured under three different conditions:
10% FBS in SFM (FBS), 10% PPP releasate in SFM (PPP) or 10%
PRPreleasate in theSFM(PRP).Thechromatographywasperformed
using dissociative conditions (see Materials and Methods section).
Percentages foreachpeak represent theproportionof [A] large (similar
to aggrecan) and [B] small (decorin, biglycan, etc.) 35S-PGs in each
group. In addition, the average partition coefﬁcient of the two mole-
cules (peak A and B) is shown as follows: (CM; [A] average
Kd ¼ 0.27, [B] average Kd ¼ 0.66/FRM; average Kd [A] ¼ 0.30,
average Kd [B]¼ 0.70).indicated the presence of type I collagen, was not detected.
This relative prominence of a1 chains suggests that the
majority of the collagen synthesized in the presence of
FBS, PPP or PRP was type II collagen, as previously de-
scribed29,30. This 95 kDa band was conﬁrmed to be immu-
nopositive to an anti-type II collagen antibody (data not
shown) and did not react with an anti-type I collagen anti-
body (data not shown).
Discussion
The study presented here is the ﬁrst to show that PRP,
a ‘‘natural cocktail’’ of growth factors obtained using a point
of care apparatus, has the potential to stimulate cell prolif-
eration and matrix metabolism of porcine articular chondro-
cytes cultured in alginate beads. At the same concentration
(10% in SFM), the stimulatory effects of PRP were stronger
than those of FBS or PPP. Furthermore, the major proﬁles
of PGs and collagens synthesized by chondrocytes in the
presence of PRP were similar to those seen in cells cul-
tured in FBS.
A platelet contains the vast majority of biologically active
molecules required for blood coagulation, such as adhesive
proteins, coagulation factors and protease inhibitors, within
cytoplasmic a-granules31. In addition to the factors that co-
agulate blood, growth factors such as TGF-b, PDGF, EGF,
vascular endothelial growth factor and IGF-1 are released
from a-granules31,32 when platelets are activated. These
growth factors are known to stimulate collagen deposition,
accelerate epithelial regeneration, promote angiogenesis,
and ultimately improve wound healing in skin and periodon-
tal tissue33e36.
Recently, the use of patient autologous PRP, which
serves as a source of growth factors able to induce tissue
regeneration, has gained wide acceptance in several surgi-
cal applications, such as bone regeneration in periodontal
and maxillofacial surgery37e39, orthopedic surgery40,
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Fig. 4. Effect of PRP treatment on PG accumulation by articular
chondrocytes cultured in alginate beads. After the 72-h treatment
period, the total sulfated PG content was measured in each com-
partment using a modiﬁed dimethylmethylene blue dye-binding
method. Articular chondrocytes cultured in alginate beads treated
with 10% PRP accumulated signiﬁcantly more PGs than those
treated with FBS (P< 0.001)) or PPP (P< 0.0001). The numbers
presented in each column indicate how much PG was present in
the CM and FRM as a percentage of the total PG content in the
beads.
1277Osteoarthritis and Cartilage Vol. 14, No. 12otolaryngology41 and plastic surgery42. The same ap-
proach, using a platelet-rich gel, was recently applied to
wound healing16,36 and cardiovascular surgery43. Those
growth factors identiﬁed in PRP independently stimulate ei-
ther cell proliferation or matrix metabolism by articular chon-
drocytes8,17,18,44,45. This study focused on the effect of PRP
on matrix synthesis and accumulation to test the practicality
of using PRP as a tissue culture supplement.
Adult minipigs were used in this study as a source of both
articular cartilage and blood. Due to the limitation in the
number of cells that could be obtained from the elbow joint
of a single minipig, cells from different animals were pooled
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Fig. 5. Effect of PRP treatment on collagen synthesis by porcine ar-
ticular chondrocytes cultured in alginate beads. The incorporation of
3H-labeled proline into pepsin-resistant protein was measured as an
indicator of collagen synthesis. During the last 16 h of the 72-h treat-
ment period, the cells were radiolabeled with L-[2,3,4,5-3H]-proline
(50 mCi/ml). Radioactivity in the pepsin-resistant radiolabeled pro-
teins was measured as described in the Materials and Methods sec-
tion. The rate of collagensynthesis of FBS-treated cellswas similar to
that of PPP-treated cells. However, the stimulatory effect on the rate
of collagen synthesis was greater in the case of PRP-treated cells
than of cells treated with FBS or PPP. The numbers presented in
each column indicate how much collagen was present in the CM,
FRM and medium as a percentage of the total 3H-labeled collagen
in the beads.
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Fig. 6. Characterization of newly synthesized collagens in CM and
FRM fractions. A ﬂuorogram of pepsin-resistant 3H-proline-labeled
proteins in the CM fractions of FBS-, PPP- and PRP-treated
groups. The radiolabeled collagens were separated by SDS-
PAGE in a 7.5% acrylamide gel (reducing conditions) and detected
by ﬂuorography. The CM fractions in each group contained a similar
prominent band at 95 kDa by SDS-PAGE ﬂuorography.to perform the experiments. Therefore, it was not possible
to use autologous PRP, which would have been preferable.
This notwithstanding, it should be noted that four different
batches of PRP from individual animals were tested and
yielded essentially similar results. Although our study to
determine the concentration of growth factors was limited
to TGF-b, a signiﬁcant concentration of TGF-b (two fold,
29.1 ng/ml) was achieved. Using human blood, further stud-
ies on the effects of donor age, length and other conditions
of storage of PRP, and biological characteristic variability
should be performed. Thrombin, which has been shown to
have some biological effects on cell metabolism, was
used to form a clot in the preparation of PRP46e49. Because
PPP was also treated with thrombin in order to control for
the effects of thrombin, it is unlikely that thrombin itself con-
tributed to the differences between the effects of PRP and
PPP on cell proliferation and matrix metabolism.
Although the PG accumulation per beads and PG synthe-
sis per DNA were signiﬁcantly upregulated by the PRP
treatment, the PG accumulation per DNA was not signiﬁ-
cantly different among the treatment groups. This suggests
that the increased sulfated PG accumulation in alginate
beads containing chondrocytes cultured with PRP was
mainly a result of increased cell proliferation induced by
the PRP treatment for 3 days. In addition, incubation in
the three different experimental conditions for a period of
3 days might not be long enough to induce a signiﬁcant dif-
ference in the PG content in alginate beads that had been
precultured for 6 days under identical conditions.
In porcine chondrocytes, the effects of PRP were more
pronounced on collagen synthesis than PG synthesis, espe-
cially when compared to cells treated with FBS. The essen-
tial role of growth factors released from platelets is to
accelerate the wound-healing process of soft tissues (such
as blood vessel walls, muscle and skin)14 or hard tissues
such as bone after injury to those tissues15; these tissues
all contain large amounts of collagen. Thus, this ‘natural
cocktail’ of growth factors included in PRP might have the
ability to preferentially promote collagen synthesis. This is
especially important because most tissue-engineered carti-
lage lacks sufﬁcient collagen when formed in vitro7,50.
Several investigators have previously reported that plate-
let lysates stimulate the cell proliferation of chondrocy-
tes51e53. However, the results on the effects of platelet
lysates on matrix accumulation differ from our results with
PRP, probably because of differences in isolation procedur-
es51e53. In the study by Choi et al.51, the ‘‘platelet lysate’’
was isolated by centrifugation and repeated freezeethawing,
while the ‘‘PRP releasate’’ used in the present study was
puriﬁed by a ‘‘point of care’’ procedure followed by clot for-
mation with thrombin. These differences in isolation may re-
sult in differences in the proportions and/or concentrations
of growth factors and other plasma components present
in ‘‘platelet lysates’’ and ‘‘PRP’’. The technical advances
in the isolation of the PRP releasate may promote its accep-
tance as a simple procedure to obtain culture supplements
that stimulate the metabolism of chondrocytes.
For clinical use, autologous chondrocyte transplantation
(ACT) has been used to repair articular cartilage defects54.
The most popular and commercially available cell-based
therapy for autologous chondrocyte implantation in the
United States is Carticel (Genzyme Biosurgery, Boston,
MA), which uses FBS in the culture process. When utilizing
FBS in culture systems for clinical use, there is a potential
risk for the transmission of animal diseases. To avoid the
risk of zoonotic transmission, the use of autologous serum
from patients is preferable in in vitro cell-based culture
1278 K. Akeda et al.: Platelet-rich plasma and chondrocytessystems55,56. BecausePRPhas the potential to stimulate cell
proliferation and matrix synthesis by articular chondrocytes,
the application of autologous PRP from patients may be an
attractive supplement for ACT, as well as tissue-engineered
cartilage. Although the identiﬁcation of factors involved in
the effect of PRP on matrix metabolism of chondrocyte was
outside the scope of this study, a study aimed at determining
the concentration of growth factors responsible for these ef-
fects and changes of concentrationwith agingwill provide im-
portant information about the limitations of this approach.
The use of PRP has several advantages over the use of
recombinant growth factors or products of animal origin.
First, as a point of care approach, the autologous prepara-
tion of PRP avoids the complex regulatory pathway. In ad-
dition, safety issues, such as immunologic reactions or
carcinogenesis, are of much less concern. Finally, the costs
of using PRP would be considerably less than those asso-
ciated with the use of recombinant proteins. If 800 ml of au-
tologous blood was collected from a patient, this would
translate into 600 ml of culture medium containing 10%
PRP and 1500 ml of 10% PPP-containing medium, making
this a feasible approach to in vitro cell-based cartilage tis-
sue engineering. For the application of PRP growth factors
to human tissue-engineered cartilage, further studies on the
effects of PRP on matrix metabolism by human primary and
passaged chondrocyte should be performed.
The results of this study provide evidence for the plausible
use of PRP to stimulate the matrix metabolism of articular
cartilage engineered in vitro. Further studies to establish
the efﬁcacy and reproducibility of PRP prepared from human
blood, especially from donors of different ages, to stimulate
chondrocyte metabolism should be performed to extend this
simple and safe new approach to the engineering of carti-
lage constructs.
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